Allotype analysis to determine the origin of cytomegalovirus immunoglobulin-G after allogeneic stem cell transplantation.

about

Allotype analysis to determine the origin of cytomegalovirus immunoglobulin-G after allogeneic stem cell transplantation.

Item

http://www.wikidata.org/entity/Q42182292

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Allotype analysis to determine ...... eic stem cell transplantation.

@en

Allotype analysis to determine ...... eic stem cell transplantation.

@nl

type

Item

label

Allotype analysis to determine ...... eic stem cell transplantation.

@en

Allotype analysis to determine ...... eic stem cell transplantation.

@nl

prefLabel

Allotype analysis to determine ...... eic stem cell transplantation.

@en

Allotype analysis to determine ...... eic stem cell transplantation.

@nl

P1476

Allotype analysis to determine ...... eic stem cell transplantation.

@en

P2093

A Tanihara

http://www.w3.org/2001/XMLSchema#string

H Nakano

http://www.w3.org/2001/XMLSchema#string

H Nakasone

http://www.w3.org/2001/XMLSchema#string

H Wada

http://www.w3.org/2001/XMLSchema#string

J Kanda

http://www.w3.org/2001/XMLSchema#string

J Nishida

http://www.w3.org/2001/XMLSchema#string

K Kawamura

http://www.w3.org/2001/XMLSchema#string

K Sakamoto

http://www.w3.org/2001/XMLSchema#string

K Terasako-Saito

http://www.w3.org/2001/XMLSchema#string

M Ashizawa

http://www.w3.org/2001/XMLSchema#string

P2860

Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex.

Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study.

Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.

Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

Evaluation of the validity of preemptive therapy against cytomegalovirus disease based on antigenemia assay with a cutoff of 20 positive cells per two slides.

The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy.

The immune response to human CMV

How we treat cytomegalovirus in hematopoietic cell transplant recipients.

Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients.

P304

904-913

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/TID.12304

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yu Akahoshi

P577

2014-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25367140

http://www.w3.org/2001/XMLSchema#string

P921

Cytomegalovirus